Clinical Trials
22 trialsNCT01627041 2026-04-27
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT00534469 2025-12-02
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
City of Hope Medical Center
Phase 2 Completed
NCT01154439 2022-10-26
AML1208
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 1 Completed
NCT00651261 2021-08-18
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Alliance for Clinical Trials in Oncology
Phase 3 Unknown
NCT00372593 2021-03-24
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
Children's Oncology Group
Phase 3 Completed
NCT00295841 2018-08-10
Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Wake Forest University Health Sciences
Phase 1 Completed
NCT01656031 2017-06-20
A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia
Wake Forest University Health Sciences
Phase 2 Completed
NCT00085709 2015-09-30
S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML
SWOG Cancer Research Network
Phase 3 Completed
NCT00407966 2015-08-04
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00101153 2015-07-23
Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
University Health Network, Toronto
Phase 1 Completed
NCT00023777 2015-03-06
S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT00096122 2014-05-26
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00093483 2014-01-13
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Completed
NCT00354276 2014-01-10
VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00112554 2013-11-06
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 3 Completed
NCT00258271 2013-10-16
Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia
University of Rochester
Phase 1 Completed
NCT00098423 2013-09-30
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 1 Completed
NCT00454480 2013-08-26
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT00006363 2013-06-04
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 3 Completed
NCT00357305 2013-05-03
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
National Cancer Institute (NCI)
Phase 1 Completed
NCT00096148 2013-01-24
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00003758 2009-02-09
Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 2 Unknown